The CASP7 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the CASP7 gene in the NCI-H1299 human lung adenocarcinoma cell line. This loss-of-function model provides a robust tool for investigating caspase-7-dependent apoptosis mechanisms within a cancer-relevant context, avoiding the clonal biases inherent in single-cell-derived knockout lines.
The host cell line, NCI-H1299, originates from a lymph node metastasis of a non-small cell lung carcinoma and is characterized by a TP53-null genotype, which confers marked resistance to apoptosis. As an epithelial line widely employed in oncology research, it serves as a metastatic model and a platform for probing drug sensitivity and cell survival pathways in lung cancer.
CASP7 encodes an executioner caspase that is activated by initiator caspases CASP8 and CASP9 in response to death receptor or mitochondrial signals, with involvement of upstream regulators such as CYCS, APAF1, and the BCL2 family. Once activated, CASP7 cleaves critical substrates including PARP1, LMNA, and DFFA, orchestrating DNA fragmentation and nuclear disassembly. Its activity is modulated by interactions with XIAP and counteracted by SMAC/DIABLO, integrating both intrinsic and extrinsic apoptotic cascades.
In the TP53-null NCI-H1299 background, disruption of CASP7 allows precise dissection of executioner caspase function in apoptosis-resistant cancer cells. The polyclonal population captures a wide range of genetic edits, enabling robust functional studies that reflect heterogeneous tumor behavior. Combining this model with chemotherapeutics or targeted agents helps reveal the dependency on CASP7 for drug-induced cell death and supports the identification of synthetic lethal interactions relevant to non-small cell lung cancer.
These knockout cells are suited for a variety of experimental approaches, including Western blotting for cleaved caspase-7 and its substrates, annexin V/propidium iodide flow cytometry, fluorogenic caspase activity assays, and cell viability profiling via MTT. They also facilitate immunofluorescence-based monitoring of apoptotic signaling and mechanistic studies of protein interactions involving regulators like XIAP and SMAC/DIABLO. For further product information or to discuss custom gene-editing services, please contact Ascent Research.
